



# ZANUBRUTINIB BTK OCCUPANCY IN PERIPHERAL BLOOD MONONUCLEAR CELLS AND IN LYMPH NODES BY DOSE REGIMENS RELATIVE TO THOSE IN IBRUTINIB


## Ibrutinib PBMC



## Zanubrutinib PBMC




## Zanubrutinib Lymph Node




# ZANUBRUTINIB AND IBRUTINIB KINASE SELECTIVITY

## Zanubrutinib



"Illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com)"

## Ibrutinib



"Illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com)"

Zanubrutinib, 71nM		Ibrutinib, 32nM	
Kinase	% inhibition	Kinase	% inhibition
1 BLK	99.9	BLK	100.2
2 ERBB4/HER4	99.1	BMX/ETK	99.7
3 TXK	98.5	ERBB4/HER4	99.5
4 BMX/ETK	98.1	TXK	98.8
5 <b>BTK</b>	<b>95.1</b>	TEC	98.0
6 TEC	79.3	<b>BTK</b>	<b>97.2</b>
7 BRK	63.9	FGR	95.7
8 FGR	53.1	YES/YES1	92.9
9 EGFR	43.3	LCK	91.2
10 LCK	40.6	ITK	84.3
11 YES/YES1	37.1	HCK	83.0
12 CSK	28.8	CSK	81.0
13 STK33	23.7	EGFR	76.5
14 BMPR2	22.6	FYN	66.9
15 AXL	22.4	ERBB2/HER2	61.9
16 HCK	21.9	SRMS	61.0
17 PKCδ	20.9	JAK3	58.7
18 FLT3	20.5	LYN	52.3
19 MEKK1	20.1	c-Src	46.1
20 ITK	19.1	FLT3	41.8
21 MSK2/RPS6KA4	19.0	BRK	41.6
22 ERN1/IRE1	17.9	ABL2/ARG	40.4
23 MNK2	17.8	WNK1	32.5
24 FRK/PTK5	17.8	MNK2	32.4

Targets with >50% inhibition highlighted in red.